Analyst Reco. Innoviva, Inc.

Equities

INVA

US45781M1018

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-07 EDT			5-day change	1st Jan Change
15.53 ^USD	+0.52%		+2.78%	-3.18%

04-24	Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	CI
03-04	Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Adjusts Price Target on Innoviva to $10 From $13, Maintains Underweight Rating	23-03-03	MT
Morgan Stanley Adjusts Price Target on Innoviva to $14 From $13, Maintains Underweight Rating	22-10-13	MT
Goldman Sachs Starts Innoviva at Neutral With $16 Price Target	22-07-20	MT
Morgan Stanley Trims Innoviva's Price Target to $12 From $13, Underweight Rating Maintained	22-07-15	MT
Morgan Stanley Raises Innoviva's Price Target to $13 From $12, Maintains Underweight Rating	22-04-12	MT
Morgan Stanley Raises Innoviva's Price Target to $12 From $10, Maintains Underweight Rating	22-02-23	MT
INNOVIVA : Morgan Stanley Adjusts Innoviva PT to $10 From $8, Maintains Underweight Rating	20-11-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW